The evolving landscape of diabetes management is experiencing a significant shift, driven by new incretin-based therapies. Currently, semaglutide has achieved considerable attention, but rival medications like https://safagiss103764.mpeblog.com/74606530/the-future-of-diabetes-comparing-tirzepatide-semaglutide-retatrutide-and-cagrilintide